Login to Your Account

Merck Picks Up Vernakalant Rights; Cardiome Energized

By Catherine Shaffer

Wednesday, July 27, 2011
The acquisition of rights to vernakalant by Merck and Co. Inc. is being greeted as a vote of confidence by investors of Cardiome Pharma Corp. The price of shares in the Vancouver, British Columbia-based company surged more than 28 percent Tuesday after it announced that it was transferring rights for development and commercialization of the drug in North America from Astellas US LLC, a subsidiary of Astellas Pharma Inc., of Tokyo, to Merck, which already had rights in other parts of the world.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription